HBM Holdings Limited (2142)

Overview

HBM Holdings Limited is a pioneering force in the biopharmaceutical sector, primarily focused on the discovery and development of unique antibody therapeutics aimed at addressing unmet medical needs in the immunology and oncology disease spheres. Established in 2016 and rooted in Shanghai, the People's Republic of China, the company extends its innovative research and development efforts across Mainland China, the United States, Europe, and other international markets. Through strategic collaborations with notable entities like LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. on antibody-drug conjugate projects, HBM Holdings Limited leverages cutting-edge science to forge pathways towards novel treatments and therapies.

Products and Services

Batoclimab (HBM9161): A groundbreaking human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor. This innovation showcases HBM Holdings' commitment to advancing solutions in the immunology therapeutic area.

HBM7008: A bispecific antibody targeting tumor associated antigens, illustrating HBM Holdings’ expertise in developing targeted therapies for the management and treatment of cancer.

HBM4003: Represents a human anti-CTLA-4 antibody aimed against the cytotoxic T-lymphocyte-associated antigen-4, underscoring the company’s endeavors in harnessing the body’s immune system to fight cancer.

HBM9378: Currently under development for the treatment of asthma, this product signifies HBM Holdings’ efforts to diversify its portfolio across different areas of immunology.

HBM1020, HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014: A robust pipeline of products devoted to the treatment of solid tumors. This expansive portfolio reflects the company’s significant investment in developing novel oncology therapeutics and its determination to address the complexities of cancer treatment with innovative solutions.